menu
    • menu
    [{"orgOrder":0,"company":"Ottimo Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Jankistomig","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ottimo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Ottimo Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"4","companyTruncated":"Ottimo Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Ottimo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Jankistomig","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ottimo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ottimo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ottimo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ottimo Pharma","sponsor":"Asimov","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"OTP-01","moa":"PD1\/VEGFR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Ottimo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottimo Pharma \/ Ottimo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ottimo Pharma \/ Ottimo Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Ottimo Pharma

    Menu

    Ottimo Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTP-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Asimov

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Asimov, Ottimo Pharma Enter Cell Line Development Partnership

                            Details : The collaboration centered on cell line development for Ottimo’s lead program, OTP-01, a PD1/VEGFR2 dual pathway antibody.

                            Product Name : OTP-01

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 27, 2025

                            Lead Product(s) : OTP-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Asimov

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Jankistomig

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : OrbiMed Advisors

                            Deal Size : $140.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ottimo Pharma Raises over $140 Million in Series A Financing

                            Details : The financing will accelerate the lead asset, Jankistomig, a PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications and a pipeline of follow-on bifunctional assets.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            December 19, 2024

                            Lead Product(s) : Jankistomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : OrbiMed Advisors

                            Deal Size : $140.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            Ottimo Pharma

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Jankistomig

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ottimo Pharma Develops PD1/VEGFR2 Antibody Backed By Medicxi, Clinic in 2025

                            Details : Ottimo is developing Jankistomig, a PD1-VEGFR2 bi-functional antibody, designed as a dual-pathway, IgG therapy targeting immune checkpoint inhibition and angiogenesis in the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            October 28, 2024

                            Lead Product(s) : Jankistomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth